Publicaciones en las que colabora con Enrique Santas Olmeda (41)

2024

  1. Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 206-214

  2. β-Blocker Withdrawal and Functional Capacity Improvement in Patients with Heart Failure with Preserved Ejection Fraction

    JAMA Cardiology, Vol. 9, Núm. 4, pp. 392-396

2023

  1. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  2. Maximal functional capacity in subjects with isolated left bundle branch block: A pilot study

    Clinical Cardiology, Vol. 46, Núm. 4, pp. 386-389

  3. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

2022

  1. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

    Scientific Reports, Vol. 12, Núm. 1

  2. Long-Term Prognostic Impact of Estimated Glomerular Filtration Rate on Admission in Patients Hospitalized for Acute Heart Failure

    CardioRenal Medicine, Vol. 12, Núm. 4, pp. 179-188

  3. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure

    Revista Espanola de Cardiologia, Vol. 75, Núm. 4, pp. 316-324

  4. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure

    European Journal of Internal Medicine, Vol. 95, pp. 67-73

  5. Sex-Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum

    Journal of the American Heart Association, Vol. 11, Núm. 1

  6. Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 11, Núm. 7, pp. e022214

  7. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

    European Journal of Heart Failure, Vol. 23, Núm. 9, pp. 1445-1457

  2. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure

    European Journal of Internal Medicine, Vol. 92, pp. 94-99

  3. Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure

    Medicina Clinica, Vol. 156, Núm. 12, pp. 589-594

  4. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

    Journal of the American College of Cardiology, Vol. 78, Núm. 21, pp. 2042-2056

  5. Iron deficiency and short-term adverse events in patients with decompensated heart failure

    Clinical Research in Cardiology, Vol. 110, Núm. 8, pp. 1292-1298

  6. Right Heart Dysfunction and Readmission Risk Across Left Ventricular Ejection Fraction Status in Patients With Acute Heart Failure

    Journal of Cardiac Failure, Vol. 27, Núm. 10, pp. 1090-1098

2020

  1. Beta-blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve-HR trial)

    Clinical Cardiology, Vol. 43, Núm. 5, pp. 423-429

  2. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

    American Journal of Medicine, Vol. 133, Núm. 3, pp. 370-380.e4